CATEGORIES: PT and Exercise | Research

A Bi-Directional, Translational Model of Resistance-Type Exercise Training in the Management of Charcot-Marie-Tooth (CMT) Disease

by | Sep 10, 2015 | 1 comment

A team of government researchers, including Dr. Robert Chetlin (Associate Professor and Clinical Director of Sports Medicine at Mercyhurst University, Research Physiology Contractor in the Division of Safety Research at CDC-NIOSH), have collaborated with Dr. Michael Sereda and Dr. Klaus Nave of the Max Planck Institute for Experimental Medicine (MPI) to successfully secure the CMT1A transgenic rat from MPI and establish a colony in the United States. Presently. Initial funding for this project was supported by the Hereditary Neuropathy Foundation (HNF, New York, NY).

These government investigators, including Dr. Chetlin, are continuing to examine the effects of a validated, evidence-based mechanical loading “resistance-type” exercise protocol on these transgenic CMT1A rats. These unique animals are trained on a specialized machine, called a dynamometer (a machine used to exercise and test force, torque, and power), using stretch-shortening contractions (SSCs; coordinated muscle lengthening and shortening movements used daily in human and animal activities).

The animals’ exercise routine is very tightly controlled, including all the training variables, such as the volume (reps and sets), intensity (how hard), duration (time per training session), frequency (number of training sessions per week), and progression (training variable increases) of exercise. The extent to which the animals had beneficially adapted to the exercise training was determined upon completion of the “resistancetype” training protocol. An integrated systems approach was utilized to examine and quantify exerciseinduced changes in:

(1) functional performance of muscle, including strength and muscular work;

(2) muscle physiology and quality and individual myofiber histomorphology (microscopic examination of muscle anatomy, function, and pathology);

(3) the nerve coating (myelin), connection between nerve and muscle (neuromuscular junction), and the nerve itself, and;

(4) the genes, proteins, and other potential “biomarkers” that may exert control over the way muscles and nerves operate and communicate with each other in response to exercise.

Collectively, these initial findings suggest that SSC-exercise training may be the preferred mode of resistance-type training, given that it enhanced static and dynamic muscle performance and muscle quality. This provides evidence suggesting that when an established fundamental model of CMT1A is mechanically loaded, using a validated, in vivo, highintensity, “resistance-type” training regimen, a dynamic adaptive response results.

This occurrence may represent a critical direction for establishing an achievable translational paradigm for increased quality-of-life and independence in human CMT patients. To our knowledge, this is the first study to integrate an established animal model of CMT and investigate the effects of a validated and adaptive, resistance-type exercise training regimen on PMP22 gene expression in muscle for any animal or human CMT population.

Given the course of these experiments, we now intend to refine the exercise exposure to identify the type, quantity, and frequency of training that provides optimal functional benefit to the transgenic CMT1A rats. Additionally, future studies will also examine the possible effects of dietary supplements, and other small-molecule therapies in the transgenic rats, with and without exercise, to determine if the combination of exercise and these other interventions are more effective than any of these approaches used alone.

A synopsis of the most recent findings, presented at the 2015 Annual Meeting of the American College of Sports Medicine (ACSM), includes:

  • SSC-exercise training protocol of 4.5 weeks duration (~6-month human equivalent), employing dynamic SSCs, elicits an adaptive response in transgenic CMT1A rats.
  • The training-related adaptive performance and physiological response improved relative isometric force production (static strength), maintenance of normalized muscle mass (a ratio of examined muscle mass to limb length), and a trend for improved static muscle quality (a ratio of isometric force to normalized muscle mass).
  • Improved dynamic (SSC) muscle function indicated by an increase in positive work and a trend for increased cyclic force (repeated SSC force); while, additionally, there was an enhancement in dynamic muscle quality (a ratio of SSC force to normalized muscle mass).
  • SSC-exercise training reduced PMP22 gene (the gene which codes for myelin production; mutations of this gene may result in CMT1A, Dejerine-Sottas Disease, or Hereditary Neuropathy with liability to Pressure Palsy) expression, which may, ultimately, improve myelin integrity (and function) in these SSCtrained animals.

Disclaimer: The information presented in this article has previously been disseminated to the public at the 2015 and the National Conference of the American College of Sports Medicine. HNF, in part sponsored this research project.

Learn more on this topic

Related Blog Posts

Sneak Peak of Fall Newsletter: CMT Research Study Survey

My name is Elizabeth Francisco and I am a graduate student from the Genetic Counseling program at the University of North Carolina Greensboro. I am inviting you to participate in a research study. The goal of my study is to learn more about the experiences of people with Charcot-Marie-Tooth (CMT) with genetic counseling and genetic testing. Adults with CMT and parents or legal guardians of someone of any age who has a diagnosis of CMT are eligible to participate

Building Awareness on CMT and Supporting the Patient Community – HNF Announces Support from Pharnext

HNFpharnext recently entered into a partnership with the French biopharmaceutical company, Pharnext, to help raise awareness of Charcot-Marie-Tooth (CMT) disease and support the CMT patient community through several initiatives. Building awareness is key! Pharnext’s support will assist HNF in distributing HNF’s CMT Update quarterly newsletter, enhancing the Global Registry for Inherited Neuropathies (GRIN), setting up activities for CMT September Awareness Month in the US and strengthening the CMT Inspire Community.

Quality of Life and CMT Research

Did you know that 95% of clinical trials fail? There are multiple causes, most related to efficacy or safety, which obviously can be harmful and risky for patients. The risk-reward of enrolling in trials is a judgment call based on the devastating effects of disease related to quality of life (QoL) or life-threatening disease. With CMT, the risk-reward is more of a challenging question for many, as CMT in most cases is non-fatal.

Personal Stories: Triathlete, Trainer with Charcot-Marie-Tooth

Personal Stories: Triathlete, Trainer with Charcot-Marie-Tooth

In spite of high foot arches and trouble with balance, Joy von Werder of Winter Springs, FL has always been a runner and cyclist. She was also eager to participate in a triathlon. “The training and racing aspects really appeal to me,” she explained. There was one huge problem though. Joy didn’t know how to swim. “So there I was, 39 years old, taking swimming lessons from the boy who gave my little kids lessons,” Joy laughs, but her voice changes quickly as she describes her first race.

Help us answer questions that your doctors and the CMT Research Community aren’t too sure about.

Did you know that you can become part of a community in therapy development and further research for all forms of CMT and inherited neuropathies? The mission of the Global Registry for Inherited neuropathies (GRIN) is to collect clinical and genetic information from patients with ALL forms of Charcot-Marie-Tooth (CMT) and other related rare and ultra rare inherited neuropathies.

Hot off the press

It seems like almost weekly there is another new publication on CMT with interesting basic biology. While an earlier “Hot off the press” highlighted the work of Cherry and co-workers at the University of Texas Southwestern Medical Center who showed show that neurons lacking a gene for rab7 result in neuropathy.

Join the conversation

Leave a Comment

1 Comment

  1. Barry Huffman

    I am 57 years old and have CMT and would like to have updates on the disease that I have managed to live with.


Submit a Comment

Your email address will not be published. Required fields are marked *


Join for notifications on events, campaigns, & news